REViVALS-1B: A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

Engensis (donaperminogene seltoplasmid) - Beijing Northland, Reyon Pharma, Helixmith

http://clinicaltrials.gov/ct2/show/NCT05176093

Nov 7, 2022